bpc-157 fda warning compounding bpc 157 human use not approved This is the first vote from the FDA's bpc-157 fda approval status warning

Sterility verification and endotoxin-free certification are required for reliable laboratory work

While some users report short-term benefits, the absence of extensive, well-conducted studies prevents us from fully understanding potential long-term risks

Oral-route preclinical evidence Published oral-route evidence includes: Accelerated healing of tendon, ligament and muscle injuries in rodents dosed orally by gavage or drinking water though typically with larger mass doses than parenteral protocols, reflecting lower bioavailability

Avoid taking it if you have: asthma cancer, especially of the breast, ovaries, uterus, prostate, hypothalamus, or pituitary gland epilepsy hCG allergy heart disease hormone-related conditions kidney disease migraines precocious (early) puberty uterine bleeding Injections of hCG are common in IVF, IUIs, and other fertility treatment